Ketamine for acute neuropathic pain in patients with spinal cord injury

Journal of Clinical Neuroscience

Volumn 20, Issue 6, 2013, Pages 804-807

  Kim, Kyongsong ^a   Mishina, Masahiro ^a   Kokubo, Rinko ^a   Nakajima, Takao ^a   Morimoto, Daijiro ^b   Isu, Toyohiko ^b   Kobayashi, Shiro ^a   Teramoto, Akira ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b KUSHIRO ROSAI HOSPITAL   (Japan)

Author keywords

Allodynia; Ketamine; Neuropathic pain; Spinal cord injury; Test challenge; Utility

Indexed keywords

KETAMINE; ANALGESIC AGENT;

ABNORMAL SENSATION; ACUTE NEUROPATHIC PAIN; ADULT; AGED; ALLODYNIA; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FLOATING SENSATION; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; NAUSEA; NEUROPATHIC PAIN; NIGHTMARE; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPINAL CORD INJURY; TREATMENT DURATION; VERY ELDERLY; VISUAL ANALOG SCALE; VOMITING; COMPLICATION; NEURALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN MEASUREMENT;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; FEMALE; HUMANS; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PROSPECTIVE STUDIES; SPINAL CORD INJURIES;

EID: 84891860102     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2012.07.009     Document Type: Article

References (36)

1. Norrbrink Budh C, Hultling C, Lundeberg T. Quality of sleep in individuals with spinal cord injury: a comparison between patients with and without pain. Spinal Cord 2005;43:85-95.
2. Shiddall PJ, McClelland JM, Rutkowski SB, et al. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003;103:249-57.
3. Winderstrom-Noga BG, Duncan R, Felipe-Cuervo E, et al. Assessment of the impact of pain and impairments associated with spinal cord injuries. Arch Phys Med Rehabil 2002;83:395-404.
4. Putzke JD, Richards JS, Hicken BL, et al. Interference due to pain following spinal cord injury: important predictors and impact on quality of life. Pain 2002;100:231-42.
5. Ravenscroft A, Ahmed YS, Burnside IG. Chronic pain after SCI. A patient survey. Spinal Cord 2000;38:611-4.
6. Budh CN, Osteraker AL. Life satisfaction in individuals with a spinal cord injury and pain. Clin Rehabil 2007;21:89-96.
7. Siddall PJ. Management of neuropathic pain following spinal cord injury: now and in the future. Spinal Cord 2009;47:352-9.
8. Westgren N, Levi R. Quality of life and traumatic spinal cord injury. Arch Phys Med Rehabil 1998;79:1433-9.
9. Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69.
10. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51.
11. Backonja M, Arndt G, Gombar KA, et al. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 1994;56:51-7.
12. Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 1995;37:1080-7.
13. Felsby S, Nielsen J, Arendt-Nielsen L, et al. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1995;64:283-91.
14. Max MB, Byas-Smith MG, Gracely RH, et al. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a doubleblind comparison to alfentanil and placebo. Clin Neuropharmacol 1995;18:360-8.
15. Kvarnström A, Karlsten R, Quiding H, et al. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand 2004;48:498-506.
16. Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician 2010;13:245-9.
17. Leung A, Wallace MS, Ridgeway B, et al. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001;91:177-87.
18. Christoph T, Schiene K, Englberger W, et al. The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. Neuropharmacology 2006;51:12-7.
19. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001;429:71-8.
20. Ditunno Jr JF, Young W, Donovan WH, et al. The international standards booklet for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Paraplegia 1994;32:70-80.
21. Kato J, Murai R, Iwasaki K, et al. The effects of the ketamine infusion on neuropathic pain. Pain Res 1995;10:105-10.
22. Oga K, Kojima T, Matsuura M, et al. Effects of low-dose ketamine on neuropathic pain: an electroencephalogram-electrooculogram/behavioral study. Psychiatry Clin Neurosci 2002;56:355-63.
23. Yamamoto T, Katayama Y, Tsubokawa T, et al. Ketamine test for the central deafferentation pain patients: comparison with the morphine/thiamylal test and the stimulation therapy. Pain Res 1994;9:109-14.
24. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990;11:307-9.
25. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983;306:686-8.
26. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44:293-9.
27. Yamamoto T, Yaksh TL Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain 1992;49:121-8.
28. Persson J, Hasselstrom J, Wiklund B, et al. The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesiol Scand 1998;42:750-8.
29. Mathisen LC, Skjelbred P, Skoglund LA, et al. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 1995;61:215-20.
30. Burton AW, Lee DH, Saab C, et al. Preemptive intrathecal ketamine injection produces a long-lasting decrease in neuropathic pain behaviors in a rat model. RegAnesth Pain Med 1999;24:208-13.
31. Woolf CJ. Long term alterations in the excitability of the flexion reflex produced by peripheral tissue injury in the chronic decerebrate rat. Pain 1984;18:325-43.
32. Sandkuhler J, Benrath J, Brechtel C, et al. Synaptic mechanisms of hyperalgesia. Prog Brain Res 2000;129:81-100.
33. Eisenberg E, Pud D. Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine? Pain 1998;74:337-9.
34. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Pharm Des 2005;11:2977-94.
35. Grant JS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. BrJAnaesth 1981;53:805-10.
36. Shimoyama M, Shimoyama N, Gorman AL, et al. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite norketamine. Pain 1999;81:85-93.